Commission Implementing Regulation (EU) 2023/113 of 16 January 2023 authorising the placing on the market of 3′-Sialyllactose sodium salt produced by derivative strains of Escherichia coli BL21(DE3) as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
1. 3′-Sialyllactose sodium salt produced with derivative strains of E. coli BL21(DE3) is authorised to be placed on the market within the Union. 3′-Sialyllactose sodium salt produced with derivative strains of E. coli BL21(DE3) shall be included in the Union list of novel foods set out in Implementing Regulation (EU) 2017/2470. 2. The Annex to Implementing Regulation (EU) 2017/2470 is amended in accordance with the Annex to this Regulation.
Only the company Chr. Hansen A/S ( 16 ) is authorised to place on the market within the Union the novel food referred to in Article 1, for a period of 5 years from 6 February 2023, unless a subsequent applicant obtains an authorisation for that novel food without reference to the scientific data protected pursuant to Article 3 or with the agreement of Chr. Hansen A/S.
The scientific data contained in the application file and fulfilling the conditions laid down in Article 26(2) of Regulation (EU) 2015/2283 shall not be used for the benefit of a subsequent applicant for a period of 5 years from the date of entry into force of this Regulation without the agreement of Chr. Hansen A/S.
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
ANNEX The Annex to Implementing Regulation (EU) 2017/2470 is amended as follows: (1) in Table 1 (Authorised novel foods), the following entry is inserted in alphabetical order: Authorised novel food Conditions under which the novel food may be used Additional specific labelling requirements Other requirements Data Protection ‘ 3′-Sialyllactose (‘3′-SL’) sodium salt (produced by derivative strains of E. coli BL21(DE3)) Specified food category Maximum levels The designation of the novel food on the labelling of the foodstuffs containing it shall be ‘3′-Sialyllactose sodium salt’. The labelling of food supplements containing 3′-Sialyllactose (3′-SL) sodium salt shall bear a statement that (a) they should not be consumed by children under 3 years of age; (b) they should not be used if other foods containing added 3′-sialyllactose sodium salt are consumed the same day. Authorised on 6 February 2023. This inclusion is based on proprietary scientific evidence and scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283. Applicant: “Chr. Hansen A/S”, Boege Allé 10-12, 2970 Hoersholm, Denmark. During the period of data protection, the novel food 3′-Sialyllactose sodium salt is authorised for placing on the market within the Union only by Chr. Hansen A/S unless a subsequent applicant obtains authorisation for the novel food without reference to the proprietary scientific evidence or scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283 or with the agreement of “Chr. Hansen A/S”. End date of the data protection: 6 February 2028.’ Infant formula as defined under Regulation (EU) No 609/2013 0,23 g/L in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer Follow-on formula as defined under Regulation (EU) No 609/2013 0,28 g/L in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer Processed cereal-based foods for infants and young children and baby foods for infants and young children as defined under Regulation (EU) No 609/2013 0,28 g/L or 0,28 g/kg in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer Milk based drinks and similar products intended for young children 0,28 g/L in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer Foods for special medical purposes for infants and young children as defined under Regulation (EU) No 609/2013 In accordance with the particular nutritional requirements of the infants and young children for whom the products are intended but in any case not higher 0,23 g/L or 0,28 g/kg in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer. Foods for special medical purposes as defined under Regulation (EU) No 609/2013 excluding foods for infants and young children In accordance with the particular nutritional requirements of the persons for whom the products are intended Food Supplements as defined in Directive 2002/46/EC, for the general population, excluding infants and young children 0,7 g/day (2) in Table 2 (Specifications), the following entry is inserted in alphabetical order: Authorised novel food Specification ‘ 3′-Sialyllactose (‘3′-SL’) sodium salt (produced by derivative strains of E. coli BL21(DE3)) Description: 3'-Sialyllactose (3′-SL) sodium salt is a purified, white to off-white powder or agglomerate produced by a microbial process and contains limited levels of lactose, 3'-sialyl-lactulose, and sialic acid. Definition: Chemical name: N-Acetyl-α-D-neuraminyl-(2→3)-β-D-galactopyranosyl-(1→4)-D-glucose, sodium salt Chemical formula: C 23 H 38 NO 19 Na Molecular mass: 655,53 Da CAS No: 128596-80-5 Source: Two genetically modified strains (a production strain and an optional degradation strain) of Escherichia coli BL21(DE3) Characteristics/Composition: 3′-Sialyllactose sodium salt (% of dry matter): ≥ 88,0 % (w/w) 3′-Sialyl-lactulose (% of dry matter): ≤ 5,0 % (w/w) D-Lactose (% of dry matter): ≤ 5,0 % (w/w) Sialic acid (% of dry matter): ≤ 1,5 % (w/w) N-acetyl-D-glucosamine (% of dry matter): ≤ 1,0 % (w/w) Sum of other carbohydrates (% of dry matter) a : ≤ 5,0 % (w/w) Moisture: ≤ 9,0 % (w/w) Ash: ≤ 8,5 % (w/w) Residual protein: ≤ 0,01 % (w/w) Sodium: ≤ 4,2 % (w/w) Microbiological criteria: Standard plate count: ≤ 1 000 *CFU/g Enterobacteriaceae: ≤ 10 CFU/g Salmonella spp.: Absence in 25 g Yeast and mould: ≤ 100 CFU/g Cronobacter ( Enterobacter ) sakazakii : Absence in 10 g Residual endotoxins: ≤ 10 **EU/mg a Sum of other carbohydrates = 100 (% (w/w) of dry matter) – 3'-Sialyllactose sodium salt (% (w/w) of dry matter) – quantified carbohydrates (% (w/w) of dry matter) – Ash (% (w/w) of dry matter); * CFU: Colony Forming Units; ** EU: Endotoxin Units’
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.